uploads/2018/10/Part8_Graph.png

Regeneron and Alnylam Collaborate for NASH Research Program

By

Updated

Regeneron and Alnylam Pharmaceuticals’ collaboration

On March 21, Regeneron (REGN) and Alnylam Pharmaceuticals (ALNY) announced that the companies had formed a collaboration to develop innovative RNAi therapeutics targeting NASH and other liver conditions. The companies plan to combine Regeneron’s research based on the role of a variant of the HSD17B13 gene in reducing the risk of NASH with Alnylam’s RNAi capabilities of targeting and silencing specific genes.

This research program is in its early stages. However, if successful, it can be a robust long-term growth driver for Regeneron and Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals (ALNY) is currently trading 1.47% higher than its 52-week-low price of $78.85 and 48.04% lower than its 52-week-high price of $153.99. 

Based on its October 15 closing price, the company has returned -3.88%, -17.63%, and -21.77%, respectively, in the last week, the last month, and the last quarter. The company has returned -18.65%, -34.95%, and -37.02%, respectively, in the last half year, the last year, and year-to-date.

Article continues below advertisement

Analysts’ recommendations and target price for Alnylam Pharmaceuticals

The 12-month consensus analyst recommendation for Alnylam Pharmaceuticals (ALNY) on October 16 was for a “buy.” The 12-month consensus target price for the company is $141.59, which is 76.97% higher than its closing price on October 15. The highest target price estimate for the company is $230.00, and the lowest target price estimate is $73.00.

Of the 17 analysts covering Alnylam Pharmaceuticals in the first half of October, the majority of the analysts are bullish on the stock. Three analysts rated the company as a “strong buy,” and 11 analysts recommended the company as a “buy.” Two analysts rated the company as a “hold,” and one analyst recommended the company as a “sell.”

At the end of the second quarter, the company had $1.45 billion in cash and $30.0 million in debt on its balance sheet.

In the next article, we’ll discuss Allergan’s stock performance.

Advertisement

More From Market Realist